THI is now producing a unique product, pharmaceutical grade Chenopodium Quinoa Saponins, which could be used, and will be used as the next generation vaccine adjuvant. THI is the only producer of this type fo saponin. Get your sample now.
2. What are quinoa titerpene saponins?
• Natural non ionic surfactants produced by plants as a defense
mechanism
• Surfactant
• Contains both water-soluble and lipid-soluble components
• Their application is growing rapidly
• Organic origin
• No synthetic-surfactant downside
3. Important facts - Quinoa saponins
• Resistant to salt & heat
• Stable to acid PH
• Low to negligible toxicity profile
• Does not accumulate over time
• High compatibility with nature
• Virtually zero contamination footprint
5. Saponin Pharmaceutical Applications
Vaccine Adjuvant
• Adjuvant effects well known (20 + years)
• Increases antigen specific antibody and T-cel response
• Potentiates weaker antigens
• Enhances duration and onset of immune response
• Used in prophylactic and therapeutic vaccines
6. Saponin Pharmaceutical Applications
Formulation Flexibility
• Potent with small amounts of antigen
• Can be used with other adjuvants and in various formulations
• Provides vaccine antigen sparing effect
• Effective via parenteral or mucosal applications
• Advantageous safety profile
7. Saponin Pharmaceutical Applications
Pre-clinical Chenopodium Quinoa Saponins
• Available directly without licensing agreements
• GMP material planned for Q2 2019
• 5 – 500 mg are in stock and ready to ship
• Samples are provided free of charge
• Discounts offered to Academic Researchers
8. Saponin Pharmaceutical Applications
Clinical Experience
• Tested in over 40,000 humans
• Currently in over 16 human vaccine candidates
• Currently used in 4 Phase III clinical trials for Malaria, Melanoma & NSCLC
• Can be used with other TLR Agonists to form adjuvant systems
• Testing underway in HIV, TB, Alzheimer's disease and various oncology
tumor type vaccine programs
9. Saponin Pharmaceutical Applications
GlaxoSmithKlein – Shingles Vaccine - Shingrix
• FDA approved on October 20, 2017 for use in human commercial vaccines
• Uses Quijalla Bark Saponin as adjuvant
• Saponins were not used as adjuvants due to lack of supply
• There were no precedents of FDA-approved saponin-adjuvant based
vaccines
• The market is now ready to adopt high purity saponins for human vaccine
use
10. Saponin Veterinary Applications
Adjuvant Overview
• Supplied as a light taupe to taupe crystals with less than 1% moisture content
• Shelf life is two years at room temperature
• Standardized in non-saponin impurities (polyphenols & polysaccharides) to
establish batch consistency
11. Saponin Veterinary Applications
Adjuvant VET-CQS 08
• It is a highly purified form of Chenopodium Quinoa Saponins handled to
reduce low molecular weight contaminants
• Provides the opportunity to formulate with one of the purest saponin
adjuvants in the market (93 - 95%+)
• Sapogenin content : 60%+ - best in class
• Product is traceable from the crop phase to its final presentation
• Supply is assured by our raw material inventories and our cooperation
agreements with local quinoa processing companies
12. Quinoa Saponin Composition
Five-ringed acid backbone
4 Main Aglycones
4 Monodesmosidic Titerpene Saponins
22 Bidesmosidic Titerpene Saponins
89 Detected and profiled saponins
• 70 verified by NMR spectroscopy
14. Quinoa Saponin Composition
• Average molecular weight 1,800 – 2,000 Daltons
• Below 200 – 500 ppm concentration => saponins exist as a monomer
• Above 200 – 500 ppm => micelles with apparent molecular weight of approximately
100,000 Daltons
15. Pharma & Vet Grade Quinoa Saponins
• Quinoa extracts need careful purification
• Purification - THI Proprietary AOSS technology (Green Tech)
• Product is made out of light-taupe to taupe crystals
• Aqueous solution has a yellow-brown appearance
Concentration 93 - 96 %+
Sapogenin 60%+
Ash 1 - 2%
Other 2 - 4%
16. Pharma & Vet Grade Quinoa Saponins
• Production can be scaled easily
• No contaminants from purification tech (AOSS)
• Can be certified as an organic ingredient
• Product not previously available
• Supply was the main road block to market incorporation
• Saponin use will phase out other traditional vaccine adjuvants
17. Titerpenic Quinoa Saponins Products
Pharma
Product : CQS-07
• Saponin content: 95%+
• Sapogenin: 60%+
• Sample: 25 g
• 25, 100 g
Veterinary
• Product : VET CQS-08
• Saponin content: 93 - 95%+
• Sapogenin: 60%+
• Sample: 25 g
• 25, 100 g
PRICING AND MSDS TO BE PROVIDED ON REQUEST
18. Sample & enquiry instructions
Andres Zavaleta
CEO
andres@terrehauteindustries.com
+591 7679-4166
Please Include the following information:
• Name:
• Company:
• Email:
• Phone number:
• Product Required:
• Intended use:
Mariana Zavaleta
VP Marketing & Sales
andres@terrehauteindustries.com
+591 7676-8504